Clinical trial

Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer

NCT01069796

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Paclitaxel Normalized identity: paclitaxelView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Bevacizumab Normalized identity: bevacizumabView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Capecitabine Normalized identity: capecitabineView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2010-04-01

PhasePHASE2

Conditions

Triple Negative Metastatic Breast Cancerunresolved

Interventions

PaclitaxelDRUG · verified · RxNorm: paclitaxel

BevacizumabDRUG · verified · RxNorm: bevacizumab

CapecitabineDRUG · verified · RxNorm: capecitabine

Sponsors & collaborators

ARCAGY/ GINECO GROUPlead sponsor

Mapped research locations

MarseilleFrance1 StrasbourgFrance1 BordeauxFrance1 NiceFrance1 RouenFrance1 AngersFrance1 ReimsFrance1 NancyFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01069796 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.